Patients may also experience profound hypoglycemia (dangerously low blood sugar), abdominal pain, and delayed gastric emptying so extreme that solid food cannot pass into the small intestine
Injectable Compounded GLP-1: $ per month Oral Compounded GLP-1: $ per month Oral Compounded GLP-1 + GIP: $ per month Injectable Compounded GLP-1 + GIP: $ per month You can cancel your subscription at anytime by logging into your Patient Portal
Normal physiological roles include: Glucose-dependent insulin secretion stimulation from pancreatic beta cells, enhancing insulin release only when blood glucose is elevated Glucagon suppression reducing hepatic glucose output and preventing excessive blood sugar elevation Gastric emptying delay prolonging nutrient absorption time and extending postprandial (after-meal) satiety signals Central nervous system effects through GLP-1 receptors in brain regions controlling appetite, promoting feelings of fullness and reducing hunger Potential beneficial effects on cardiovascular function, though mechanisms remain under investigation Pharmaceutical GLP-1 Agonist Engineering: Semaglutide and similar medications are synthetic analogs modified to: Resist rapid degradation by DPP-4 enzyme that normally breaks down natural GLP-1 within minutes Achieve substantially longer half-life enabling once-weekly dosing versus continuous natural GLP-1 secretion Maintain high receptor binding affinity providing consistent GLP-1 receptor stimulation Cross blood-brain barrier accessing central appetite regulation pathways Effects on Appetite Regulation and Caloric Intake: Clinical research documents several mechanisms reducing food consumption: Increased satiety (feeling of fullness) and earlier meal termination due to delayed gastric emptying Reduced hunger between meals through central nervous system appetite suppression Decreased food cravings particularly for high-calorie, high-fat, and high-sugar foods Possible effects on reward pathways reducing hedonic eating (eating for pleasure rather than hunger) Slowed gastric emptying creating prolonged physical sensation of fullness after smaller portions Key Clinical Trial Data from FDA-Approved Semaglutide STEP 1 Clinical Trial Results: This pivotal study established efficacy for Wegovy (semaglutide 2.4mg for weight management): 1,961 adults with BMI 30 kg/m or 27 kg/m with weight-related comorbidities 68-week randomized, double-blind, placebo-controlled trial Both groups received intensive lifestyle intervention including diet counseling and exercise encouragement Primary outcome: Average 14.9% body weight reduction with semaglutide versus 2.4% with placebo 86.4% of semaglutide participants achieved 5% weight loss (clinically meaningful) versus 31.5% placebo 69.1% achieved 10% weight loss versus 12% placebo 50.5% achieved 15% weight loss versus 4.9% placebo Improvements in cardiovascular risk factors including blood pressure, lipid profiles, inflammatory markers STEP 2 Trial in Patients with Type 2 Diabetes: Participants with diabetes often experience less weight loss due to metabolic differences Average 9.6% weight reduction with semaglutide 2.4mg versus 3.4% with placebo Additional glycemic control benefits beyond weight loss including HbA1C reductions Demonstrates effectiveness across different patient populations STEP 4 Weight Maintenance Trial: 20-week run-in period where all participants received semaglutide and achieved weight loss Randomization to continued treatment versus switch to placebo Continued semaglutide group maintained weight loss with additional modest reductions Placebo withdrawal group regained significant weight (average 6.9% regain over 48 weeks) Critical evidence that ongoing treatment needed to sustain results - weight loss not permanent after discontinuation Important Contextual Factors: Clinical trials enrolled highly selected populations meeting specific inclusion/exclusion criteria All participants received intensive lifestyle intervention support beyond just medication Trial settings provided regular monitoring, accountability, and professional guidance often exceeding real-world conditions Results represent averages with substantial individual variability - some patients lose much more, others much less Clinical Trial Applicability Disclaimer: Weight loss outcomes from controlled clinical trials of FDA-approved branded semaglutide medications should not be assumed to apply directly to compounded semaglutide formulations, which have not undergone similar rigorous clinical testing
Breast Cancer Signs and Symptoms Breast Cancer Signs and Symptoms to Watch For Any thickening (increased density or firmness) in the breast tissue in or near the breast or underarm area A change in skin texture or enlarged pores in the skin of the breast or nipple (may resemble an orange peel) Any unexplained change in the size or shape of the breast, or breasts suddenly seem asymmetrical Dimpling anywhere on the breast Unexplained swelling of the breast (especially on one side only) Unexplained shrinkage of the breast (especially on one side only) Nipple is tender, or turned slightly inward or inverted The skin of the breast, areola (darker skin surrounding the nipple), or nipple has become scaly, red, or swollen Any nipple discharge, especially clear or bloody discharge The Signs and Symptoms of Breast Cancer Symptoms of Paget Disease of the Breast In Paget disease of the breast, cancerous cells called Paget cells are found in the surface layer of the skin of the nipple and the areola
Lauterburg BH
